



CERTIFICATE OF MAILING  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT  
POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:  
ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231,  
ON March 10, 2003.

Audrey Boyd  
March 10, 2003  
DATE

1625  
**RECEIVED**  
MAR 21 2003  
TECH CENTER 1600/2900 #10B  
M.M.  
3/26/03

Attorney Docket No.: P32292

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Blackler, et al.

Appln. No.: 10/048,123

Group Art Unit: 1625

Filed: December 22, 2002

Examiner: B.M. Robinson

For: THIAZOLIDINEDIONE DERIVATIVE AND ITS USE AS ANTIDIABETIC

Assistant Commissioner for Patents  
Washington, D.C. 20231

AMENDMENT AND INFORMATION DISCLOSURE STATEMENT

Sir:

In response to the Office Action dated September 10, 2002, please amend the above-identified application as follows. A request for a three (3) month extension of time, through March 10, 2003, along with a request to deduct appropriate fees, is also included. In the event that such request becomes separated from this paper, authorization is hereby granted to charge any necessary fees under 37 C.F.R. §1.17 to Deposit Account 19-2570.

IN THE CLAIMS:

Kindly cancel claims 1-10 and 14, without prejudice or disclaimer.

Please add claims 15-34 as follows:

15. (New) A polymorph which is a polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, wherein said polymorph has:

(i) an infra red spectrum containing peaks at 1763, 912, 856 and 709 cm<sup>-1</sup>;